This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurology  • Cognitive Disorders  • Psychopharmacology  • Schizophrenia  • Alert me on articles by topic  Social Bookmarking   What's this?

Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial

R. Walter Heinrichs, PhD

Arch Gen Psychiatry. 2007;64(6):631-632.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Schizophrenia is an illness that expresses itself in severe disturbances of thought and behavior. These disturbances include strikingly implausible and bizarre beliefs, suspicions, and interpretations of experience. However, it is not just the contents of thought or what the person with schizophrenia thinks about that is abnormal. The illness also involves deficiencies in thinking with routine and relatively impersonal information and in using this information to solve problems and guide action. Psychiatric pioneers including Kraepelin¹ and Bleuler² recognized this more fundamental cognitive disturbance in schizophrenia at the beginning of the 20th century. Kraepelin suggested that the frontal and temporal lobes of the brain must be affected and characterized the syndrome as a dementia of young people, yet objective evaluation of cognitive brain function has appeared rather recently as a key tool in the study of this complex disorder. Prior to the 1990s, neuropsychological test performance was . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Richard S. E. Keefe, Robert M. Bilder, Sonia M. Davis, Philip D. Harvey, Barton W. Palmer, James M. Gold, Herbert Y. Meltzer, Michael F. Green, George Capuano, T. Scott Stroup, Joseph P. McEvoy, Marvin S. Swartz, Robert A. Rosenheck, Diana O. Perkins, Clarence E. Davis, John K. Hsiao, Jeffrey A. Lieberman, and for the CATIE Investigators and the Neurocognitive Working Group
Arch Gen Psychiatry. 2007;64(6):633-647.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Attention Shaping: a Reward-Based Learning Method to Enhance Skills Training Outcomes in Schizophrenia
Silverstein et al.
Schizophr Bull 2009;35:222-232.
ABSTRACT | FULL TEXT  

Do Antipsychotic Drugs Improve Cognitive Function in Schizophrenia?
JWatch Psychiatry 2007;2007:4-4.
FULL TEXT